Unknown PHASE2 INTERVENTIONAL NCT00039169

BAY 59-8862 in Treating Patients With Advanced Kidney Cancer

An Uncontrolled Phase II Multi-Center Trial Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Advanced Renal Cell Cancer

Sponsor: Theradex

Conditions Kidney Cancer

Interventions ortataxel

Updated 6 times since 2017 Last updated: Jul 23, 2008 Started: Dec 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Kidney Cancer, this trial is ongoing. The trial is conducted by Theradex and has accumulated 6 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theradex

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Billings, United States , Calgary, Canada , Edmonton, Canada , Greenbelt, United States , La Jolla, United States , Milwaukee, United States , Muncie, United States , New Brunswick, United States , New Orleans, United States and 3 more locations